Invasive group B streptococcal disease in infants: a 19-year nationwide study. Serotype distribution, incidence and recurrent infection

Ekelund, Kim; Konradsen, Helle Bossen

doi:10.1017/s0950268804002808

Cited by 36 publications

(36 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By contrast, GBS has only nine serotypes, but a higher proportion of invasive isolates are nontypeable (8,12,21). S. pneumoniae serotyping uses many different, often cross-reacting antisera to identify serotypes (15), whereas each of the nine GBS serotypes has a single specific antiserum.…”

Section: Discussionmentioning

confidence: 99%

Serotype IX, a Proposed New Streptococcus agalactiae Serotype

et al. 2007

View full text Add to dashboard Cite

We identified three isolates of Streptococcus agalactiae (group B streptococcus [GBS]), of human origin, which failed to react with antisera against any of the nine known GBS serotypes. Polyclonal rabbit antisera raised against these isolates and standard GBS typing sera were used in capillary precipitation and Ouchterlony tests to compare the strains with known GBS serotype reference strains. All three previously nontypeable isolates reacted with all three new antisera, producing lines of identity in the Ouchterlony test. Weak crossreactions with antisera against several GBS serotypes were observed but were removed by absorption with corresponding antigens. The new antisera were used to test 227 GBS isolates that had been nontypeable or difficult to type using standard antisera. Of these, five reacted with the new antisera. These results suggested that all eight isolates belong to the previously unrecognized GBS serotype. They were tested by Western blotting for the C␣ and C␤ proteins and by PCR to identify molecular serotypes and surface protein antigen genes. Two segments of the cps gene cluster (3 end of cpsE-cpsF and 5 end of cpsG, approximately 700 bp; 3 end of cpsH and 5 end of cpsM, approximately 560 bp) were sequenced. All eight isolates expressed C␣, and seven expressing the C␤ protein and the corresponding genes, bca and bac, respectively, were identified. They all share the same, unique partial cps sequence. These results indicate that these eight isolates represent a new S. agalactiae serotype, which we propose should be designated serotype IX.

show abstract

Section: Discussionmentioning

confidence: 99%

Serotype IX, a Proposed New Streptococcus agalactiae Serotype

et al. 2007

View full text Add to dashboard Cite

show abstract

“…We also gathered data on potential explanatory variables (ie, variables that might explain variance in incidence or risk of group B streptococcus; 21 Andersen et al 22 Ekelund et al 23 Kuhn et al 24 Fluegge et al 25 Berardi et al 26 Trijbels-Smeulders et al 27 van den Hoogen et al 28 Hasseltvedt et al 29 Hajdu et al 30 Neto et al 31 Janek et al 32 Carbonell-Estrany et al 33 Lopez Sastre et al 34 Andreu et al 35 Persson et al 36 Heath et al 37 Oddie et al 38 Weisner et al 39 Vergnano et al 40 Subtotal (I 2 =98·6%, p=0·000)…”

Section: Data Extractionmentioning

confidence: 99%

Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis

Edmond¹,

Kortsalioudaki²,

Scott³

et al. 2012

The Lancet

528

457

View full text Add to dashboard Cite

SummaryBackground Despite widespread use of intrapartum antibiotic prophylaxis, group B streptococcus remains a leading cause of morbidity and mortality in infants in Europe, the Americas, and Australia. However, estimates of disease burden in many countries outside of these regions is not available. We aimed to examine the current global burden of invasive disease and the serotype distribution of group B streptococcus isolates.

show abstract

“…Streptococcus agalactiae (group B streptococcus, GBS) is the most common cause of neonatal (Ekelund & Konradsen, 2004) and obstetric sepsis, and is an increasingly important cause of septicaemia in the elderly and in immunocompromised patients (Schuchat et al, 2002;Tyrrell et al, 2000). There has been considerable progress in the development of conjugate polysaccharide GBS vaccines (Paoletti & Madoff, 2002).…”

Section: Introductionmentioning

confidence: 99%

Simultaneous detection and serotype identification of Streptococcus agalactiae using multiplex PCR and reverse line blot hybridization

Kong

Gilbert

2005

Journal of Medical Microbiology

View full text Add to dashboard Cite

Streptococcus agalactiae (group B streptococcus, GBS) is an important cause of sepsis in neonates and their mothers, and the elderly and immunocompromised patients. Ongoing surveillance to monitor GBS serotype distribution is needed to guide the development and assess the feasibility of GBS conjugate vaccines. The authors previously developed a molecular serotype identification method based on serotype-specific PCR and partial sequencing of cps genes. In this study, a novel 10-primer pair multiplex PCR and reverse line blot (mPCR/RLB) hybridization assay was developed for simultaneous detection and serotype identification of all nine GBS serotypes. For all 316 GBS isolates tested the mPCR/RLB results corresponded with those of conventional serotyping and individual serotype-specific PCR, and the method was more convenient and practical than either alternative.

show abstract

Invasive group B streptococcal disease in infants: a 19-year nationwide study. Serotype distribution, incidence and recurrent infection

Cited by 36 publications

References 39 publications

Serotype IX, a Proposed New Streptococcus agalactiae Serotype

Serotype IX, a Proposed New Streptococcus agalactiae Serotype

Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis

Simultaneous detection and serotype identification of Streptococcus agalactiae using multiplex PCR and reverse line blot hybridization

Contact Info

Product

Resources

About